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Methods:We infected a panel of 30 inbred strains ofmicewith RSV andmeasured changes in lungdisease param-
eters 1 and 5 days post-infection and they were used in genome-wide association (GWA) studies to identify
quantitative trait loci (QTL) and susceptibility gene candidates.
Findings: GWA identiﬁed QTLs for RSV disease phenotypes, and the innate immunity scavenger receptor Marco
was a candidate susceptibility gene; targeted deletion ofMarcoworsenedmurine RSV disease.We characterized
a humanMARCO promoter SNP that caused loss of gene expression, increased in vitro cellular response to RSV
infection, and associated with increased risk of disease severity in two independent populations of children in-
fected with RSV.
Interpretation: Translational integration of a genetic animalmodel and in vitro human studies identiﬁed a role for
MARCO in human RSV disease severity. Because no RSV vaccines are approved for clinical use, genetic studies
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C-ND lic1. Introduction
RSV is the primary cause for hospitalization during the ﬁrst year of
life in infants worldwide, and it is the leading cause of lower respiratory
tract infection leading to bronchiolitis, pneumonia, and respiratory fail-
ure (Lozano et al., 2012). RSV is also a signiﬁcant cause of respiratory ill-
ness in immunocompromised adults and the elderly (Falsey et al.,
2005). While the majority of infected subjects present symptoms, the
nature and severity of the symptoms vary among individuals
(Ciencewicki et al., 2014; Caballero et al., 2015). For some, infection in-
duces cold-like symptoms; others require hospitalization, and a smallense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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wide variation in response to RSV infection suggests that susceptibility
and disease are inﬂuenced by multiple host intrinsic factors (Stark et
al., 2002; Miyairi and DeVincenzo, 2008; Gelfand, 2012; Feldman et
al., 2015).
Previous in vivo mouse studies suggest that RSV infectivity is a mul-
tigenic trait, but did not identify the genes responsible for infection
(Prince et al., 1979; Stark et al., 2002; Stark et al., 2010). The innate
and acquired immune systems have been implicated in the pathogene-
sis of RSV infection, including surfactant association proteins, viral re-
sponse receptors and proteins, and inﬂammatory cells and their
products such as chemokines, cytokines, and soluble inﬂammatory me-
diators [e.g. (Mukherjee and Lukacs, 2013; Varga and Braciale, 2013)].
However, roles for each of these components in the pathogenesis of
RSV disease are unclear.
RSV disease is complex and, while candidate gene single nucleotide
polymorphisms (SNPs) have associated with RSV disease severity in
infants [e.g. (Miyairi and DeVincenzo, 2008; Daley et al., 2012;
Ciencewicki et al., 2014; Caballero et al., 2015)], the mechanisms of dif-
ferential disease susceptibility remain unclear. To better understand the
genetic basis of RSV disease, we performed a genome-wide association
(GWA) study of disease following infection in inbred strains of mice to
identify candidate quantitative trait loci (QTL) and genes that associate
with speciﬁc disease phenotypes. We identiﬁed 7 signiﬁcant and 8 sug-
gestive QTLs and candidate susceptibility genes including macrophage
receptor with collagenous structure (Marco), an innate immunity scav-
enger receptor. Targeted deletion of mouse Marco worsened RSV dis-
ease phenotypes, consistent with a protective role in disease
pathogenesis. We then identiﬁed and characterized in vitro a human
MARCO promoter SNP that diminished mRNA expression basally and
after RSV infection. The SNP is located in an antioxidant response ele-
ment (ARE) of theMARCO promoter and is a binding site for the tran-
scription factor nuclear factor (erythroid derived)-2 like 2 (NFE2L2),
also known as nuclear factor erythroid 2 (NF-E2)-related factor 2
(NRF2). Deletion of the ARE also reducedMARCOmRNA expression fol-
lowing RSV infection in airway epithelial cells. Moreover, compared to
the wild-type C allele, we found that the MARCO promoter rs1318645
SNP G allele associated with increased disease severity in populations
of RSV-infected infants. Our modeling of disease after RSV infection in
mice thus identiﬁed a host susceptibility gene candidate that has impli-
cations for better understanding human disease.
2. Materials and Methods
2.1. Mice and Treatments
Mice from 30 inbred strains (male, 6–10weeks) for the strain screen
were purchased from Jackson Laboratory (Bar Harbor, ME) and housed
singly with hardwood bedding (PJ Murphy Forest Products Company,
Montville, NJ) in pathogen-free facilities at NIEHS. A breeding colony
ofMarco deﬁcient mice (Marco−/−) was developed and maintained at
NIEHS (Arredouani et al., 2004; Cho et al., 2012). Age- and sex-matched
C57BL/6 wild-type (WT) mice were purchased from Charles River Lab-
oratories (Wilmington, MA) and used as controls for experiments with
the Marco−/− mice. All mice were provided free access to water and
pelleted open-formula rodent diet NIH-07 (Zeigler Brothers, Gardners,
PA.). Constant air temperature (72 ± 3° F), relative humidity (50 ±
15%), and light/dark cycle (12 h on/12 h off) were maintained during
the experiments. Mice of each strain were randomly assigned to either
RSV infection or vehicle control groups.Micewere infected in themorn-
ing with 106 plaque-forming units (PFU) of human RSV-19 strain in
50 μl Hank's balanced salt solution (HBSS) by intranasal instillation,
and returned to their cages. HBSS containing HEp-2 cell lysates were in-
tranasally instilled for vehicle controls. On post-instillation days 1 and 5,
mice (6–12 per group)were killed by overdosewith Nembutal (sodium
pentobarbital; 104 mg/kg body weight). Phenotyping for response toRSV infection was performed in at least two separate experiments
(n ≥ 3 per group), and power calculations based on previous studies
were used to determine sample sizes. All animal use was approved by
the NIEHS Animal Care and Use Committee. Animals were treated hu-
manely and with regard to alleviation of suffering.
2.2. Lung Bronchoalveolar Lavage Fluid (BALF) and Cell Preparation
The right lung of each mouse was lavaged in situ consecutively four
times with HBSS (35 ml/kg body weight, pH 7.2–7.4) and BALF was an-
alyzed for cell differentials using standard morphological and cytologi-
cal criteria as described previously (Saltini et al., 1984; Cho et al.,
2001). Total protein content (a marker of lung permeability) was mea-
sured with the Bradford assay as previously described (Cho et al., 2001;
Cho et al., 2007). Investigators were blinded to treatment for all lavage
and histopathology samples (see below). Time points chosen for evalu-
ation of inﬂammation and injurywere based on a previous investigation
of phenotype kinetics in lungs of a panel of 5 inbred strains of mice in-
fected with RSV (data not shown). We found that the peaks of inﬂam-
mation and injury phenotypes are time-dependent and usually occur
either 1 or 5 days after infection as described previously (Cho et al.,
2009).
2.3. Lung Histopathology
Left lung lobes were inﬂated intratracheally in situ and ﬁxed with
10% neutral buffered zinc formalin for 24 h following procedures de-
scribed previously (Cho et al., 2009). Fixed lungs were then placed in
70% ethanol until proximal and distal intrapulmonary axial tissues
were excised and embedded in parafﬁn and sectioned (5 μm). Tissue
sections were stained histochemically with hematoxylin and eosin
(H&E) for histopathological analyses and alcian blue-periodic acid
shift (AB/PAS) double staining to identify acidic and neutral
mucosubstances (Cho et al., 2009).
2.4. Measurement of Stored Intraepithelial Mucus (Volume Density, VS)
Images of histological sections were captured using an Axioskop 40
microscope, camera, and Axiovision software. Black and white images
were taken with a 10× objective lens and analyzed with Scion image
analysis software. The mucus-containing area and the perimeter of
basal lamina from large airways, visually judged to be third generation
bronchus, were used for analysis. The volume of mucus per airway
was calculated as described previously (Harkema et al., 1987).
VS values (nl/mm2 basal lamina) were calculated for each lung sec-
tion and averaged for vehicle control and RSV infected groups. VS calcu-
lations were averaged for each treatment group and are reported as the
mean ± SEM for each strain (n = 3/infection/strain).
2.5. Quantitative Real-time Polymerase Chain Reaction (qRT-PCR)
Total RNA was isolated from non-lavaged left lung pieces using
RNeasy Mini Kits (Qiagen, Valencia, CA) following manufacturer proce-
dures and as described previously (Cho et al., 2009). Quantiﬁcation of
gene expressionwas determined by ΔCT values obtained by subtracting
ﬂuorescence detected number of cycles to threshold (CT) of 18s mRNA
from those of target gene RNA in the same sample.
2.6. Heritability and Correlation of Phenotypes
Heritability estimates were calculated following methods described
previously (Lightfoot et al., 2004; Nichols et al., 2014). Heritability
estimates N 35%were considered sufﬁcient for GWA studies with 30 in-
bred strains ofmice (Tsaih and Korstanje, 2009). Relatedness of RSVdis-
ease phenotypes was done using Pearson's correlation coefﬁcients
(Gene Network, http://www.genenetwork.org). The maximum
75M. High et al. / EBioMedicine 11 (2016) 73–84response [1 or 5 days post-infection (PI)] for each phenotype was used
for all analyses.2.7. Genome-wide Association Mapping
GWAmappingwas performed using themean value for each pheno-
type for each strain. Data for each strain were distributed normally (no
outliers removed), and no transformations were applied. We also gen-
erated a RSV disease index by performing a principal components
(PC) analysis of each quantitated phenotype and then applied the ﬁrst
3 PCs for each strain to haplotype association mapping. Two different
haplotype-based approaches were used: SNPster (Genomics Institute,
Novartis Research Foundation, San Diego, CA) and FastMap (University
of North Carolina, Chapel Hill, NC). The algorithms (Pletcher et al., 2004;
Gatti et al., 2009) and rationale for using these approaches have been
described elsewhere (McClurg et al., 2006; Nichols et al., 2014). Exper-
imental informative SNP genotypes for GWAmapping were selected as
described previously (Benton et al., 2012). The SNPs used for the 30
strains ofmicewere fully genotyped (i.e. not imputed).−Log10 P values
were considered signiﬁcant if they exceeded 6.60 (genome-wide signif-
icance at P b 0.05) and suggestive if they exceeded 6.06 (genome-wide
suggestive at P b 0.20). Only QTLs that were identiﬁed using both algo-
rithms were considered further for candidate gene analyses. Candidate
gene SNP and haplotype data were obtained from the Mouse Phenome
Database (MPD; Jackson Laboratory; http://phenome.jax.org; dbSNP
138 annotation). Non-informative SNPs (i.e. no heterozygosity between
strains or the minor allele was found in b10% of the strains) were re-
moved from further haplotype and SNP analyses. Marco haplotype
data were obtained from the MPD, and hierarchical clustering was per-
formed as described previously (Cho et al., 2015).2.8. Sequencing of MARCO Promoter and Functional Assessment
We used traditional walk-down sequencing to identify regions of
MARCO that were polymorphic, and conﬁrmed these sites by screening
an ethnically diverse panel of individuals for allelic variation. Regions
with SNPs at 5% or higher frequencywere used in promoter deletion ex-
periments to test for effects on transcriptional activity. Constructs were
generated to encompass the full length of theMARCOpromoter (−1388
to +98), and polymorphic regions were sequentially deleted to assess
differential activity.
Initial promoter deletion assays identiﬁed a polymorphic region of
the MARCO promoter with high activity (−300 and +98) that
contained a putative NRF2-binding ARE. To determine whether the
SNP region inﬂuenced transcript levels, the −300 to +98 region of
MARCO containing the rs1318645,−156 C/G SNP (−157) was cloned
upstream of the luciferase reporter gene and its expression analyzed
by transient transfection using reporter assays. The−300 to−71 pro-
moter region was further investigated by generating two constructs
[−300 to +98 bp, (300-Luc) and−71 to +98 bp (71-Luc, lacking the
SNP)] and comparing their promoter activity.
To examine effects of the promoter SNP on transcriptional activity,
we ampliﬁed the 5′-ﬂanking region of genomic MARCO promoter to
generate polymorphic variants of the 300-Luc sequence [−156 C-Luc
and−156 G-Luc]. All constructs were veriﬁed by sequencing, and tran-
siently transfected using FugeneHD(Promega,Madison,WI) into BEAS-
2B cells (The American Type Culture Collection, Manassas, VA), and an-
alyzed for luciferase activity as described previously (Cho et al., 2015).
For RSV infectionwe used the pGL4.20 vector, and Beas2B cells were
transfected withMARCO promoter constructs (−156 C-Luc,−156 G-
Luc or −71-Luc) overnight and were serum starved for 1 h during
RSV infection (MOI of 4). Cells were harvested 3, 6, 24, 48 and 72 h
post-infection. Luciferase activity was assessed in three independent
samples and all experiments were repeated in triplicate.2.9. Electrophoretic Mobility Shift Assay (EMSA)
EMSA allows visualization of transcription factor binding afﬁnity to
regulatory promoter sequences in the presence of variant alleles.
DNA-protein binding speciﬁcity was further assessed using antibodies
speciﬁc to the binding factor of interest. An aliquot (5 μg) of human
lung nuclear protein (Active Motif, Carlsbad, CA) was incubated on ice
with binding buffer for 15 min, followed by addition of 3 × 104 cpm
[γ32P] ATP (Amersham Biosciences, Piscataway, NJ) end-labeled wild
type or variant probes (End-labeled probes: rs1318645−156 C (wt)
FORWARD 5′-CCT GGG AGT GAC GGG TGC ATT CAG AG-3′, REVERSE
5′-CT CTG AAT GCA CCC GTC ACT CCC AGG-3′; rs1318645−156G (var-
iant) FORWARD 5′-CCT GGG AGT GAG GGG TGC ATT CAG AG-3′, RE-
VERSE 5′-CT CTG AAT GCA CCC CTC ACT CCC AGG-3′) and incubated
for 30 min at room temperature. We used short (26 base pairs) frag-
ment sequences for the EMSA experiments that overlap the consensus
sequence for NRF2. We used polyclonal rabbit anti-NRF2 antiserum
(2 μl) or control IgG (2 μl) as controls and processed for EMSA as de-
scribed previously (Marzec et al., 2007). Samples were electrophoresed
and autoradiographed with an intensifying screen at−70 °C. Genotyp-
ing was done without knowledge of disease status (i.e. blinded to case
or control). We tested for statistically signiﬁcant differences in DNA-
NRF2-antibody complex formation between wild-type, heterozygous,
and variant genotypes using one-way ANOVA with SNK a posteriori
comparisons of means.
2.10. Human RSV Disease Population
Two independent prospective case-control studies were conducted
in Buenos Aires, Argentina from 2003 to 2006 (population 1) and
2010–2013 (population 2); these studies, with inclusion and exclusion
criteria, were described previously (Caballero et al., 2015). Study partic-
ipants were previously healthy full-term infants younger than 1 year of
age and born after 15 September of the previous year (i.e. approximate-
ly 15 days after the end of RSV season in Buenos Aires). Participants had
bronchiolitis symptoms for the ﬁrst time in their lives, and clinical signs
includedwheezingwith orwithout cough, rales, dyspnea, and increased
respiratory rate and retractions of the respiratory muscles. Diagnosis
was performed by trained pediatricians. Infants were tested for
RSV, rhinoviruses, hPIV1–4, inﬂuenza virus A and B, and human
metapneumovirus, and all participating subjects were infected only
with RSV. Recruited caseswere infantswith bronchiolitis whose oxygen
saturation upon enrollment was b93% in room air (the primary out-
come). Oxygen saturation is a clinically relevant phenotype for discrim-
inating between mild and severe RSV disease (Caballero et al., 2015).
Infants with bronchiolitis were recruited as controls if oxygen satura-
tion upon enrollment was ≥93% while breathing room air. Genotyping
of infants was performed using whole blood samples (population 1)
or nasal aspirates (population 2). Population sizes were based on calcu-
lations to provide sufﬁcient statistical power (~80%) to ﬁnd signiﬁcant
differences between mild and severe disease with a minor allele fre-
quency of ~0.2. The Institutional Review Boards (IRB) of the participat-
ing hospitals in Buenos Aires, as well as the Johns Hopkins University
IRB (Baltimore, MD, USA), approved the protocol. We obtained in-
formed consent from parents of each infant enrolled in the studies.
The study conformed to standards indicated by the Declaration of
Helsinki.
2.11. Allelic Discrimination Genotyping for MARCO rs1318645
Genomic DNAwas isolated and characterized for purity and concen-
tration as described previously (Caballero et al., 2015). The MARCO
rs1318645 promoter variant was assessed by allelic discrimination
with a predesigned SNP genotyping assay from Applied Biosystems.
PCR was performed using 20 μl reactions with 5 ng of genomic DNA,
10 μl of TaqMan 2XPCR Master Mix, and 1.0 μl of 20× pre-optimized
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and reverse primers and 8 μM of each allele-speciﬁc ﬂuorescently la-
beled (VIC or FAM) TaqMan MGB probe. Standard PCR cycling condi-
tions were used as described previously (Caballero et al., 2015).
Allele-speciﬁc PCR products were detected and veriﬁed as described
previously (Caballero et al., 2015). Five percent of the samples were re-
peated for quality control, and we found 100% concordance.a
c
e
b
d
0.549
Fig. 1. Lung phenotypes in representativemouse strainswithmild and severe disease after infec
disease) and BALB/cJ (severe disease) mice following vehicle or RSV infection (1, 5 days PI). Me
Newman-Keuls a posteriori tests. *P b 0.05 versus vehicle. +P b 0.05 versus C3H/HeJ. (c) Repre
mice following vehicle and RSV infection (1, 5 days PI). (d) Representative AB/PAS double s
following vehicle and RSV infection (1, 5 days PI). Arrows = areas of increased airway inﬂamm
or bronchiole, BV = blood vessel. Bar = 100 μm. (e) Circular node and edge representatio
correlation coefﬁcients (R) noted on edges (solid lines) indicate associations between phenoty2.12. Statistical Analysis
Lavage and tissue parameters were analyzed by 3-way ANOVA (fac-
tors: exposure, time, strain) and Student-Newman-Keuls (SNK) com-
parisons of means procedures. Strain distribution patterns and Marco
haplotype groups were analyzed by 1-way ANOVA and SNK compari-
sons of means. Statistical associations between candidate gene0.855
0.544
0.610
tionwith RSV. Numbers of PMNs (a) andmonocytes (b) found in BALF fromC3H/HeJ (mild
an ± SEM (n= 6–12mice/group). Groups were analyzed by 3-way ANOVA and Student-
sentative H&E stained lung sections from C3H/HeJ (mild disease) and A/J (severe disease)
tained lung sections from BTBR_T + _tf/J (mild disease) and SJL/J (severe disease) mice
ation and bronchial epithelial proliferation (hyperplasia). AV = Alveoli, BR = bronchus
n of relatedness between RSV response phenotypes among all mouse strains. Pearson
pes. R values ≥ 0.48, P b 0.05; R values ≥ 0.73, P b 0.01.
77M. High et al. / EBioMedicine 11 (2016) 73–84genotypes and phenotypes within mouse strains were calculated using
the two-tailed Student's t-test. Only the signiﬁcance of murine non-
synonymous coding SNPs were tested in this study; if more than one
non-synonymous coding SNP was found within a gene multiple com-
parisons were performed. Because of potential bias effects of admixture
in our human study populations, we followedmethods described previ-
ously to test for evidence of bias due to population stratiﬁcation
(Epstein et al., 2007) using 33 ancestral informative markers (AIMs;
Suppl. Table S1) that were evaluated in 300 infants with mild or severe
RSV disease. Genotyping was performed on the Sequenom iPlex plat-
form by BioServe (Beltsville, MD, USA). In the two infant populations,
we used χ2 analyses (dominant and recessive modeling; SigmaPlot
13.0) to test for associations betweenMARCO genotypes and RSV dis-
ease severity. We assessed potential confounding of demographic vari-
ables in the relationships between MARCO genotype and RSV disease
severity using an additivemodel formultiple logistic regressions. Statis-
tical signiﬁcance in these and all other comparisons was accepted at
P b 0.05.d
c
b
a
Fig. 2. Lung disease phenotypes in mice infected with RSV. Maximum numbers of BALF
monocytes (a), lymphocytes (b), and PMNs (c), and RSV-N mRNA expression (d) in
lung homogenates. Bars, means ± SEM (n = 6–12/group). Horizontal brackets
(monocytes) indicate means are not signiﬁcantly (P b 0.05) different from each other
(1-way ANOVA and Student-Newman-Keuls comparisons of means).3. Results
3.1. Phenotypic Characterization of RSV Disease in Inbred Mice
We developed a genetic model of RSV disease by infecting intra-
nasally 30 strains of mice. Inﬂammation was assessed in BALF by
measuring total protein concentration and counting inﬂammatory
and epithelial cells 1 and 5 days PI. The time courses of inﬂammation
and injury phenotypes indicated early (acute) and late phase re-
sponses in all of the strains tested. Relative to vehicle controls,
mean numbers of total cells, polymorphonuclear leukocytes
(PMNs), epithelial cells, and total protein in BALF of infected mice
were signiﬁcantly increased 1 day PI and declined 5 days PI in the
majority (N50%) of strains (representative strains, Fig. 1a; all strains,
Suppl. Table S2). Numbers of BALF macrophages, lymphocytes, and
monocytes (representative strains, Fig. 1b; all strains, Suppl. Table
S2) peaked at 5 days PI in the majority of strains. The differences in
kinetics may reﬂect the sequential contributions of the innate and
acquired immune systems in response to infection as others have
found [e.g. (Kok et al., 2012; Stoppelenburg et al., 2013)]. Qualitative
inspection of lung histopathology sections was consistent with BALF
inﬂammation phenotypes (Fig. 1c). Mucus cell metaplasia is a clini-
cal feature of RSV disease, and we found the mean amount of
intraepithelial cell mucus (Fig. 1d; Suppl. Table S2) and lung RSV-N
mRNA expression (Suppl. Table S2) were greatest 1 day PI in 59%
and 70% of the strains, respectively.
We also found statistically signiﬁcant inter-strain variation in the
peak of each RSV disease phenotype. That is, signiﬁcantly smaller num-
bers of inﬂammatory cells and other indicators of injury (mild disease)
were found in a subset of strains (e.g. C3H/HeJ) compared to otherswith
severe disease (e.g. BALB/cByJ) (Fig. 2a–d; Suppl. Table S2; Suppl. Fig.
S1). Heritability estimates of RSV disease phenotypes ranged from
47.6% (BALF protein, 1 day PI) to 85.7% (intraepithelial mucus, 1 day
PI) (Suppl. Table S2). To better understand mechanisms of response to
RSV infection,we tested for correlation of disease phenotypes. Pearson's
correlation analyses of RSV disease phenotypes among 30 strains found
that responses 1 day PI did not correlate with responses 5 days PI (data
not shown). When maximum responses for each parameter were com-
pared, few were signiﬁcantly correlated (Fig. 1e; Fig. 2). Interestingly,
RSV-N mRNA expression was not correlated with any response pheno-
type, a ﬁnding consistent with lack of correlation we found between
RSV disease severity and RSV titers in infected children (Caballero et
al., 2015). Large inter-strain variation and relatively high heritability of
distinct disease phenotypes suggests the mouse model of response to
RSV infection is multi-genic and mimics the variability of RSV disease
severity found in human populations.3.2. Identiﬁcation of QTLs and Gene Candidates for RSV Disease Phenotypes
Because the phenotypic responses to RSV infection were largely not
correlated, we reasoned that the phenotypes may have some QTLs in
common, but likely also have unique QTLs. Therefore, we used GWA
mapping to identify QTLs for each phenotype across the entire inbred
strain data set. Using the maximum mean response phenotypes for
each strain, mapping with SNPster identiﬁed signiﬁcant (−Log10
P N 6.6) QTLs for RSV-induced changes in BAL monocytes (chromo-
somes 1 and 17; Fig. 3a, Table 1) and PMNs (chromosomes 3 and 8;
Table 1), and the ﬁrst PC (chromosomes 4, 11, and 13; Table 1). Sugges-
tive QTLs (−Log10 P N 6.0) were also found for intraepithelial mucus
content (chromosomes 7 and 15), BALF total protein concentration
(chromosomes 9 and 19), and lung RSV-N mRNA expression (chromo-
somes 1 and 11) (Table 1). Importantly, all QTLs were also identiﬁed
using FastMap (data not shown). GWA mapping of other RSV response
phenotypeswith SNPster did not identify signiﬁcant or suggestive QTLS,
or were not conﬁrmed with FastMap.
To further investigate genetic contributions to RSV disease pheno-
types we searched the MPD for informative SNPs in susceptibility gene
candidates within signiﬁcant and suggestive QTLs, and whether they
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investigation if they had biological plausibility for a role in RSV disease
and if the minor allele of candidate SNPs were present in ≥10% of thephenotyped inbred strains. Eleven gene candidates were identiﬁed in
9 QTLs that met these criteria and also contained SNPs that associated
with differential susceptibility to an RSV disease phenotype (Table 2),
Table 1
Quantitative trait loci (QTL) type, genomic location, and maximum−Log10 P value iden-
tiﬁed by haplotype association mapping using SNPster and FastMap in 30 inbred strains
of mice.
Phenotype Chromosome QTL type Genomic location (Mb) Max
−Log10 P
Monocytes 1 Signiﬁcant 122.292051–123.591461 8.0764
17 Signiﬁcant 63.717121–63.851568 6.2074
Lymphocytes 1 Suggestive 52.516061–52.626962 4.2831
4 Suggestive 154.164390–154.306615a 4.5528
11 Suggestive 32.132950–33.743190a 4.6383
PMNs 3 Signiﬁcant 90.189278–92.304415 7.0324
8 Signiﬁcant 116.222735–121.343307 6.1851
Mucus 7 Suggestive 130.318155–130.535201 4.2492
15 Suggestive 10.421905–11.278506 4.3576
Protein 9 Suggestive 99.381216–99.610367 5.8803
19 Suggestive 42.164991–42.683021 5.2600
RSV N 1 Suggestive 92.939552–93.424360 4.5088
1 Suggestive 151.202928–152.311735 4.8599
11 Suggestive 116.303373–116.468685 4.5465
PC 1 4 Signiﬁcant 153.237964–154.148432a 6.6645
11 Signiﬁcant 31.520635–32.654798a 6.8655
13 Signiﬁcant 60.210819–60.772421 6.7123
PC1, ﬁrst principal component.
a Overlaps with another QTL.
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severity.
We focused initially on the chromosome 1 QTL formonocyte inﬂam-
mation to validate gene candidates because this QTL (~1.299 Mb) had
the greatest GWA −Log10 P value (Table 2). The scavenger receptor
geneMarco is located in the QTL (Fig. 3b) and is in linkage disequilibri-
um (LD)with the SNP that has the highest−Log P value in the QTL, and
humanMARCO is upregulated in children infected with RSV [i.e. biolog-
ical plausibility (Fjaerli et al., 2006)]. Hierarchical clustering of Marco
SNPs identiﬁed 3 major haplotypes in the strain panel (Fig. 3c; Suppl.
Table S3). Mean numbers of RSV-induced BAL monocytes in strains
from Marco haplotypes 2 and 3 were signiﬁcantly greater than those
in strains from wild-type haplotype 1 (Fig. 3d). Potentially functional,
informative SNPs are located inMarco, including the non-synonymous
coding SNP rs30741725 (A/T) that causes a threonine to serine substitu-
tion at the 476 amino acid residue in exon 17. Signiﬁcantly increased
numbers of BAL monocytes and lymphocytes 5 days PI were found in
strains of mice with the minor T allele for this SNP compared with
strains that have the major A allele (Table 2; Suppl. Fig. S2A and S2B).
The majority of strains with the T allele haveMarco haplotypes 2 or 3.
The rs30741725 A/T SNP is in LD with other SNPs in the Marco haplo-
type, so a deﬁnitive role for this SNP in differential RSV responsiveness
requires further investigation. There are 5 other protein-coding genes
in the QTL withMarco, but none have known biological plausibility for
the RSV response phenotypes or do not meet criteria for further study
(stated above).
3.3. Genetic Deletion of MarcoModiﬁes RSV-induced Pulmonary Inﬂamma-
tory Response
We further investigated the role ofMarco on RSV disease severity by
infecting Marco+/+ and Marco−/− mice with RSV. Relative to vehicle
controls, RSV increased BALF monocytes in Marco+/+ and Marco−/−
mice, and numbers of monocytes in Marco−/− mice were slightly
lower compared to Marco+/+ mice 1 day PI, during the development
of themonocyte response. However, numberswere signiﬁcantly greater
inMarco−/−mice compared to those inMarco+/+ mice at the peak of
the response (5 days PI; Fig. 3e, left). Mean numbers of PMNs were
also signiﬁcantly increased in Marco+/+ and Marco−/− mice 1 day
PI, but were signiﬁcantly greater in Marco−/− mice compared to
Marco+/+ mice, and remained signiﬁcantly elevated at 5 days PI
(Fig. 3e, right). BALF inﬂammation phenotypes were consistent with
lung histopathology sections from Marco+/+ and Marco−/− mice
(Fig. 3f). No signiﬁcant genotype effects were found for other RSV
BALF phenotypes (data not shown). Lack of resolution of the PMN
response in Marco−/− mice is consistent with the hypothesis that
inﬂammatory cell clearance is impaired in these mice.
3.4. Functional Assessment of the Human MARCO Promoter
Based on our GWA investigation and identiﬁcation of Marco as a
gene candidate for differential RSV disease severity in the mouse, we
queried dbSNP (build 129, 2008) to identify potentially relevant SNPs
in human MARCO based on functional annotation. A missense SNPFig. 3. Genome-wide haplotype association map of BALF monocytes in 30mouse strains infecte
infection. (a) Manhattan plot for maximum mean BALF monocytes in 30 strains of mice. X ax
rectangle on chromosome 1 identiﬁes a locus signiﬁcantly associated with RSV-induced mon
infection. The gene Marco is indicated within the locus. (c) Hierarchical clustering of 29 mo
uncertainty in genotype changes after clustering (Φ), where Φ= 1− cluster entropy / crude
if Φ= 0, the genotype distribution within the cluster is as variable as the genotype distributio
in strains withMarco haplotypes 1, 2, and 3. The boundary of the box closest to zero indicate
box farthest from zero indicates the 75th percentile. Error bars above and below the box indi
versus Marco haplotype 1 (1-way ANOVA and Student-Newman-Keuls comparisons of mean
Marco−/−mice. Means (±SEM) of monocytes (left) and PMNs (right) recovered in BALF afte
way ANOVA with Student-Newman-Keuls comparisons of means). (f) Pulmonary pathology
Arrows indicate areas of increased airway inﬂammation and bronchial epithelial proliferation (h(rs61732822, Asp511Glu) in the scavenger receptor cysteine rich
(SRCR) domain of exon 17 (similar to that found in mouse Marco), is
predicted by SIFT (sift.jcvi.org) to have deleterious consequences, but
the 1000 genomes project phase 1 (www.1000genomes.org) indicates
the alternate allele frequency of 0.055 is too low to study in our popula-
tions of childrenwith RSV-induced bronchiolitis.We then askedwheth-
er theMARCO promoter contains polymorphic regions that might alter
transcriptional efﬁciency. We consecutively deleted sections of the pro-
moter from−1388 to−71 and probed for transcriptional activity using
luciferase reporter constructs. We identiﬁed a region close to the tran-
scription start site (−300 to−71) that, when deleted, signiﬁcantly re-
duced transcriptional activity (Fig. 4a). We then screened commercially
available DNA samples (n = 40; Coriell Institute, Camden, NJ) for
SNPs in the MARCO promoter region. Forty subjects (20 European,
20 African-American) were chosen to provide a detection rate of
98% for SNPs present in as little as 5% of the population. The screen
identiﬁed a SNP (rs1318645, −156 C/G; Suppl. Fig. S3) that
contained a putative antioxidant response element for NRF2 [C al-
lele, position weight matrix (PWM) score = 10.9; G allele, PWM
score = 7.5]. Mutation of the −156 site from C (wild type) to G
completely reduced luciferase activity to that of the pGL3 basic vec-
tor (Fig. 4b).
Polymorphic and ARE deletion constructs cloned in BEAS-2B epithe-
lial cells were also assessed for transcriptional activity following RSV in-
fection. Robust MARCO activation was found 3, 6 and 24 h PI, and
mutation from C to G at the−156 site reduced activity approximately
50% at 6 h PI, and constructs with ARE deletion caused similar reduction
in activity (Fig. 4c). At 24 h PI, luciferase activity in constructs with ARE
deletion was reduced by 50% compared to that of wild type −300Cdwith RSV andMarco haplotype clustering and monocytic inﬂammatory response to RSV
is, chromosome number and cumulative genomic position; Y axis,−Log10 P values. The
ocyte inﬁltration. (b) Detailed view of the chromosome 1 QTL for monocyte response to
use strains based on 87 Marco SNPs (http://phenome.jax.org/SNP). Numbers represent
entropy. If, after clustering, all strains in the cluster have the same genotype thenΦ= 1;
n across all strains. (d) Box plots of numbers of BALF monocytes following RSV infection
s the 25th percentile, a line within the box marks the median, and the boundary of the
cate the 90th and 10th percentiles. Outlying points are shown for haplotype 1. *P b 0.05
s). (e) Differential pulmonary disease phenotypes after RSV infection in Marco+/+ and
r vehicle or RSV infection. *P b 0.05 versus vehicle; +P b 0.05 versusMarco+/+ mice (3-
1 and 5 days following vehicle control or RSV infection inMarco+/+ and Marco−/−mice.
yperplasia). AV=Alveoli, BR=bronchus or bronchiole, BV=blood vessel. Bar=100 μm.
Table 2
Associations of candidate gene functional single nucleotide polymorphisms (SNPs) with RSV-induced lung inﬂammation phenotypes.
Phenotype QTL chromosome Gene symbol SNP rs ID Location (Mb) SNP function Major allele, mean ± SEM, N Minor allele, mean ± SEM, N P-value
Monocytes 1 Marco rs30741725 120.474787 CNSyn, Thr476Ser A, 38.4 ± 8.8; 19 T, 14.5 ± 2.7; 10 b0.001
Lymphocytes 11 Mpg rs26841220 32.231754 CNSyn, Arg254Gln G, 28.9 ± 6.1; 24 A, 80.6 ± 22.6; 6 0.004
PMNs 3 Lor rs31130301 91.885023 CNSyn, Gly293Arg G, 134.3 ± 18.8, 16 C, 275.2.5 ± 50.4; 12 0.005
8 Adamts18 rs37229383 116.233617 CNSyn, Gly957Arg G, 226.1 ± 34.1; 21 C, 116.2 ± 24.3; 7 0.046
Mucus 7 Aqp8 rs32822168 123.462409 5′ UTR A, 1.13 ± 0.3; 24 C, 0.6 ± 0.2; 3 NS
Protein 19 Sfrp5 S19-42272711 42.272711 3′ UTR C, 342.1 ± 32.3; 19 T, 222.2 ± 13.4; 7 0.042
RSV-N 1 Ramp1 rs47959958 91.206647 3′ UTR A, 5.6 ± 0.3; 14 G, 2.3 ± 0.3; 12 b0.001
Espnl rs48467891 91.320153 CNSyn, Gly406Ser G, 4.8 ± 0.5; 19 A, 2.8 ± 0.4; 11 0.011
Per2 rs32164384 91.445550 CNSyn, Ser172Thr G, 4.7 ± 0.4; 21 C, 2.4 ± 0.4; 9 0.003
1 Ptgs2 rs32559831 151.948631 Intronic A, 5.1 ± 0.5; 14 T, 2.5 ± 0.4; 10 b0.001
11 Rhbdf2 rs29403288 116.471777 3′ UTR C, 4.9 ± 0.4; 20 T, 2.4 ± 0.5; 7 0.005
PC1 11 Mpg rs26841220 32.231754 CNSyn, Arg254Gln G,−0.50 ± 0.3; 24 A, 1.99 ± 0.1; 6 b0.001
Adamts18, a disintegrin-like andmetallopeptidase (reprolysin type)with thrombospondin type 1motif, 18; Aqp8, aquaporin 8; CNSyn, non-synonymous coding SNP; Espnl, espin-like; Lor,
loricrin;Marco, macrophage receptor with collagenous structure;Mpg, N-methylpurine-DNA glycosylase; Per2, period circadian clock 2; PC1, ﬁrst principal component; Ptgs2, prostaglan-
din-endoperoxide synthase 2; Ramp1, receptor (calcitonin) activity modifying protein 1; Rhbdf2, rhomboid 5 homolog 2 (Drosophila); Sfrp5, secreted frizzled-related sequence protein 5;
UTR, untranslated region.
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and 72 h PI (data not shown).
Gel shift analysis showed reduced NRF2 speciﬁc binding in the pres-
ence of the variant G allele in the potential ARE (Fig. 4d), suggesting
binding efﬁciency is altered at this polymorphic site. Overall binding
was increased with the G allele, suggesting additional factors may
bind this regulatory locus.3.5. Role of MARCO rs1318645 in RSV Disease Severity
Next we asked whether theMARCO SNP rs1318645 that caused re-
duced MARCO gene expression in vitro (see above) associated with in-
creased risk of severe RSV disease in populations of infected infants
from our prospective case-control study (Ciencewicki et al., 2014;
Caballero et al., 2015). Demographic characteristics are described else-
where (Caballero et al., 2015). Genotyped (Fig. 5a) infants with mild
and severe infection had combined allelic frequencies (Suppl. Table
S4) similar to those published previously (http://www.1000genomes.
org/). We were unable to successfully genotype 39 infants in the ﬁrst
population and 25 in the second population, and there was no associa-
tion of unsuccessful genotyping between cases and controls. Allelic fre-
quencies satisﬁed Hardy-Weinberg equilibrium (P = 0.369) and,
although admixture was present we found no evidence of bias due to
population stratiﬁcation (i.e. stratiﬁcation was not predictive of differ-
ential RSV disease severity). χ2 analysis of RSV disease severity found
the rs1318645 C/G polymorphism was associated with increased risk
of severe RSV disease (Fig. 5b; χ2 = 5.15, P = 0.053). The association
was largely attributed to GG risk effect (recessive model) where infants
homozygous for theG allelewere at signiﬁcant risk of developing severe
RSV disease compared to CC and CG genotypes (Suppl. Table S5). In a
second, independent population, we found theMARCO rs1318645 C/G
allele was again associated with RSV disease severity in infected infants
(Fig. 5b; χ2=8.15, P=0.017) and similar to theﬁrst population, the as-
sociation was driven by GG genotype (Suppl. Table S5). Association of
theMARCO rs1318645 C/G allele with RSV disease severity in the com-
bined population was signiﬁcantly strengthened compared to either
population alone (Fig. 5b; χ2 = 10.34, P= 0.003), and the homozygous
GG genotype conferred approximately 62% greater risk of severe RSV
disease compared to CC and CG genotypes (Suppl. Table S5). Usingmul-
tiple logistic regression we found theMARCO rs1318645 C/G allele was
associated with increased risk of severe RSV disease (unadjusted OR:
1.654, 95% CI: 0.98, 2.58). After adjusting for gender, socioeconomic sta-
tus, and breastfeeding the SNP remained associated with severe RSV
disease (adjusted OR: 1.684, 95% CI: 1.03, 3.15). Similar outcomes
were found in the second population (unadjusted OR: 1.744, 95% CI:
1.10, 2.44; adjusted OR: 1.82, 95% CI: 1.13, 2.56) and in the combinedpopulations (unadjusted OR: 1.615, 95% CI: 1.24, 2.35; adjusted OR:
1.676, 95% CI: 1.28, 2.45).4. Discussion
The impact of RSVdisease, particularly in vulnerable infants, remains
a global public health concern (Lozano et al., 2012). Unfortunately, no
RSV vaccines are approved for clinical use. Therefore, it is critical to
identify host risk factors that lead to development of prevention and in-
tervention strategies to reduce risk of RSV disease morbidity and mor-
tality, as well as asthma incidence because RSV disease has been
identiﬁed as a predisposing risk factor (Dakhama et al., 2005; Edwards
et al., 2012; Gelfand, 2012; Feldman et al., 2015). Our study used ge-
nome-wide association analyses of RSV disease parameters that model
human disease to identify biologically plausible susceptibility gene can-
didates, including Marco. Moreover, a missense loss of function poly-
morphism in the human MARCO homolog also associated with severe
RSV disease in two populations of infected infants, and illustrates the
utility of a genetic mouse model for understanding human disease. Im-
portantly, this study provides additional genetic insight thatmay lead to
a means to identify individuals at risk for severe RSV disease.
Considerable evidence has suggested that genetic background is an
important host determinant of RSV disease severity, but full characteri-
zation of susceptibility genes for this complex disease remains unclear.
Previous genetic investigations of human RSV disease have questioned
whether polymorphisms in gene candidates associate with innate and
acquired immune responses to infection and have provided some
understanding of susceptibility factors. Gene candidates in these
studies were chosen because of prior knowledge about biological
plausibility. We comprehensively characterized RSV disease pheno-
types in a large panel of inbred strains representing genetic diversity
that is present in the mouse genome. We found signiﬁcant variation
and robust heritability in each RSV disease phenotype between the
strains. However, relatedness betweenmaximum response phenotypes
wasminimal, suggestingmultiple genetic pathways likely contribute to
the responses.
Anh and Desmecht (2006) reported that pneumonia virus of mice
(PMV, the murine form of RSV) infection in a panel of 6 strains caused
strain-speciﬁc histopathologic inﬂammatory effects, decreased body
weight, and changes in pulmonary function particularly 5–7 days PI.
The studies are not directly comparable because mice were infected
with different viruses and late phase PI times investigated, but the
inter-strain variation in phenotypes is consistent with our ﬁndings.
Others (Stark et al., 2002) compared RSV infection in 8 inbred strains
and found signiﬁcant inter-strain variation in infectivity at 4 days PI,
but histopathologic changes were minimal and cellular effects were
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when acute virus effects on histopathology were no longer present.
We leveraged extensive genetic diversity among the 30 strains of
mice to perform GWA of multiple RSV disease phenotypes and thus
were not guided a priori by hypotheses about the role of speciﬁc
genes. Signiﬁcant and suggestive QTLswere identiﬁed for inﬂammatory
cells, intraepithelial cell mucus, and RSV N mRNA expression. Several
genes that may contribute to viral response, pulmonary inﬂammation,and cytokine trafﬁcking were found within the identiﬁed QTLs [e.g.
Ptgs2 (Obata et al., 2013), Ramp1 (Li et al., 2014), Rhbdf2 (Issuree et
al., 2013)], and putative functional SNPs in the genes associated with
differential RSV disease phenotypes among the strains. SNPs in other
QTL genes strongly associated with disease phenotypes and, while little
is known about their function in infectious disease, they may be impor-
tant targets for future investigation of their roles in RSV disease progres-
sion.We also found signiﬁcant QTLs using the ﬁrst PC as an RSV disease
index. Two of these QTLs overlapped those found for lymphocytes, and
suggests that further investigation of genes within the QTLs could pro-
vide greater understanding of disease susceptibility. Future GWA inves-
tigations using PC analyses may provide additional insight to disease
pathogenesis beyond using single phenotypes. Interestingly, genome-
wide linkage analyses of RSV infectivity in back-cross and F2 popula-
tions derived from C57BL/6J and AKR/J mice by Stark et al. (2010) iden-
tiﬁed a QTL on chromosome 6 that associated with increased
susceptibility to infection, though disease phenotypes were not pre-
sented. While GWA in the present investigation identiﬁed suggestive
QTLs on chromosomes 1 and 11 for RSV-N mRNA expression, none
were detected on chromosome 6. Differences in study design (e.g. hap-
lotype mapping with many strains versus linkage analysis with 2
strains, PI time differences) may have contributed to this discrepancy.
We focused on the gene candidateMarco, which was identiﬁed by
GWA for monocytes, and has been shown previously to have protective
effects in the lung following inhalation of particulate matter, exposure
to ozone, and bacterial infection (Arredouani et al., 2005; Dahl et al.,
2007; Thakur et al., 2008; Thakur et al., 2009; Ghosh et al., 2011).
MARCO gene expression was also upregulated in children infected
with RSV (Fjaerli et al., 2006). Our hypothesis that Marco contributes
to defense against RSV-induced pulmonary inﬂammation was support-
ed by two lines of evidence. First, strains ofmicewith aMarco haplotype
containing the T allele of missense coding SNP rs30741725 were at
greater risk of developing more severe RSV disease compared to strains
with the wild type A allele. Second, numbers of BALF monocytes and
PMNs were signiﬁcantly increased in Marco−/− mice compared to
Marco+/+ mice. The mechanism through which Marcomodulates the
inﬂammatory response to RSV is not completely understood.We initial-
ly hypothesized thatMarco has a direct role in clearing RSV from the air-
ways, perhaps binding the virus for internal degradation by
macrophages. To test this hypothesis, we infectedwith RSV lungmacro-
phages isolated fromMarco+/+ andMarco−/−mice but found no differ-
ences in infectivity, with and without co-culturing with epithelial cells
(data not shown). Marco also has an important role in clearance of ap-
optotic cells (Rogers et al., 2009; Getts et al., 2014), and recent studies
have targeted Marco receptors with immune-modifying particles to re-
solve monocytic inﬂammation (Getts et al., 2014). It is plausible thatFig. 4. Effect of a genetic polymorphism on in vitroMARCO promoter activity. (a) Deletion
analysis of theMARCO promoter compared to pGL3 basic vector. *P b 0.05 versus−300-
Luc; group sizes = 4. (b) Mutagenesis analysis of the MARCO rs1318645 variant
(−156G) compared to pGL3 basic vector. Bars (means ± SEM) represent luciferase
activity in basic vector, control−156 C allele, and mutant−156 G constructs. Flanking
sequence forMARCO rs1318645 is shown at top with the NRF2 response element boxed.
*P b 0.05 versus −156 C (P = 0.001); group sizes = 4. Statistical analyses, one-way
ANOVA and Student-Newman-Keuls comparisons of means. (c) Luciferase activity of
RSV infectedMARCO reporter constructs. MARCO promoter constructs were transiently
transfected and cells infected with RSV (MOI of 4). Bars (means ± SEM) represent
luciferase responses after no RSV (control) or 3–72 h post-infection (PI). Cells were
harvested 3–72 h PI and relative luciferase activity assessed. *P b 0.05 versus RSV-
infected −300_C (WT); +P b 0.05 versus No RSV control; group sizes = 6. Statistical
analyses, 2-way ANOVA and Student-Newman-Keuls comparisons of means. (d) Gel
shift analysis of MARCO promoter variants. Gel shift analysis of MARCO−156 CC (wild
type), GC and GG (variant) oligos show increased overall binding in the presence of the
G allele. Incubation with NRF2 antibody shows reduced MARCO:NRF2 speciﬁc binding
with the variant G allele. This suggests theMARCO G allele affects efﬁcient binding to the
NRF2 ARE site, and may alter transcriptional activity. A representative gel shift is shown;
group sizes n = 3. Single arrowhead, overall binding; double arrowhead, MARCO:NRF2
speciﬁc binding. FP is free radiolabeled probe, B is bound, NRF2 is NRF2 antibody, IgG is
control serum, and Cold is competition without antibody (40×).
Fig. 5. Effect of theMARCO rs1318645 C/G polymorphism on human RSV disease severity.
(a) Representative electropherograms of theMARCO promoter and putative NRF2 binding
site with the rs1318645 C/G polymorphism. (b). Role ofMARCO rs1318645 C/G in disease
severity among two populations of infants infected with RSV. Infants with mild or severe
RSV disease were genotyped for the MARCO SNP and determined to be homozygous for
the major (C) or minor (G) allele, or heterozygous. χ2 analysis of disease severity among
the three genotypes was done independently for both populations and the two
combined. *P b 0.05 versus the CC and CG genotypes.
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and apoptotic cells which leads to accumulation of these cells in the air-
ways, further contributing to RSV disease pathology. Impaired resolu-
tion of the inﬂammatory response to RSV infection and more severe
disease in Marco−/− mice compared to Marco+/+ mice is consistent
with this hypothesis.
It is important to note that Marco does not account for all of the
monocyte inﬂammation caused by RSV infection. Targeted deletion of
Marco signiﬁcantly increased susceptibility to some RSV-induced phe-
notypes but did not account for all of the genetic variation identiﬁed
by the strain screen. The background strain (C57BL/6 in this model, a
moderate responder to RSV) likely contributes to part of this difference
as the choice of background can inﬂuence the effect of targeted deletion
in mice [e.g. (Baleato et al., 2008; Leontyev et al., 2012)]. Perhaps more
importantly, other QTLs were also identiﬁed by the GWA and gene can-
didates within them also contribute to the genetic component of the
phenotype. Further investigation of these QTLs should provide addition-
al insight to the genetic contribution to RSV disease susceptibility.
BecauseMarcohad an important role inmodulating the inﬂammato-
ry response elicited by RSV, we sought to determine whether human
MARCOwas also important in RSV disease.We initially queriedwhether
theMARCO rs1318645−156 C/G SNP caused loss of function because it
was located in an ARE proximal to the transcription start site. Others
had found that the transcription factor NRF2, which binds to AREs to in-
crease gene transcription, had a role in Marco expression in mice(Harvey et al., 2011; Bonilla et al., 2013). We showed previously that
murine Marco bears a potentially functional ARE for Nrf2 binding
(−940 region, PWM score = 8.9) in a model of neonate acute lung in-
jury (Cho et al., 2012). In the present study, we found that deletion of
the ARE and mutating the−156 site in an ARE in human MARCO also
signiﬁcantly attenuated gene expression aswell asMARCO:NRF2 specif-
ic binding. Moreover, deletion of the ARE also signiﬁcantly reduced ex-
pression of MARCO in cells infected with RSV thus suggesting an
important role for the ARE and the rs1318645 −156 C/G SNP in
MARCO function, basally and in response to viral infection. This is sup-
ported by our previous study inwhich increased lung injury and inﬂam-
mation were found in Nrf2 deﬁcient mice compared to wild type mice
after RSV infection (Cho et al., 2009).
We further investigated the role ofMARCO in human RSV disease by
asking whether the missense MARCO rs1318645 G allele was more
prevalent in infected children with severe disease. In two independent
populations, infected children homozygous for the rs1318645 G allele
were more likely to have severe RSV disease than children who were
heterozygous orwild-type for the C allele. The signiﬁcance of the risk ef-
fect was increased when the populations were combined. TheMARCO
promoter SNP increased the risk for severe RSVdisease by approximate-
ly 62%. A previous investigation testedwhether 9 non-synonymous cod-
ing variants or tag SNPs inMARCO associated with chronic obstructive
pulmonary disease and found no association, although one of the SNPs
(rs41279766) associated with the risk of sepsis (Thomsen et al.,
2013). Another study found tag SNPs associated with increased risk of
pulmonary tuberculosis, while another was associated with resistance
(Bowdish et al., 2013), thus the role ofMARCO in this disease is not clear.
A caveat for this investigation is that, although we tested for a num-
ber of potential co-factors in our studies, it is possible that other con-
founders or unmeasured environmental factors may contribute to the
differences in disease severity that associated with the MARCO
rs1318645G allele. For example, gender has been found to be important
in susceptibility to some lung diseases in mouse models (Carey et al.,
2007; Cabello et al., 2015). In the present study, we used only male
mice. Although we are not aware of sexual dimorphism effects in RSV
disease, male and female mice respond differentially to inﬂuenza A in-
fection (Larcombe et al., 2011). Another important RSV disease pheno-
type is airways hyperreactivity (Yoo et al., 2013). We chose to focus
the present studies on the inﬂammation and injury responses to RSV in-
fection, but investigations into the genetic basis of susceptibility to RSV-
induced airway hyperreactivitymay also identify important susceptibil-
ity genes. It is also feasible that different strain distribution patternsmay
be foundwith a different line of RSV. Lukacs et al. (2006) found that dif-
ferent strains of RSV of the same antigenic subgroupmay cause different
RSV-induced phenotypes in BALB/cJ mice, and it is possible that other
strains also respond differently tomultiple RSV lines. Finally, it is impor-
tant to emphasize that, while the rs1318645 SNP associated signiﬁcant-
ly with RSV disease in these populations, other gene polymorphisms
also contribute to susceptibility, including myxovirus (inﬂuenza virus)
resistance 1 (MX1) (Ciencewicki et al., 2014) and toll-like receptor 4
(TLR4) (Caballero et al., 2015), and interactions between these and
other, unknown, genetic contributions remain to be clariﬁed. It is likely
that continued investigation of gene candidates identiﬁedwith GWA for
all of the phenotypes in themousemodel will add to our understanding
of RSV disease susceptibility.
In conclusion, this translational investigation identiﬁed gene candi-
dates, including Marco, for host susceptibility to multiple phenotypes
of RSV disease in mice that closely mimic human disease, and a poly-
morphism in humanMARCO associated with increased risk of RSV dis-
ease severity in infants. Continued investigation of the genetic basis of
differential susceptibility to RSV disease may lead to a panel of informa-
tive SNPs to identify children who are at risk for disease severity. In the
absence of anRSVvaccine, these individuals could be treated prophylac-
tically with an RSV monoclonal antibody to prevent infection and se-
quelae associated with severe disease such as childhood asthma.
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